Characterization of synovial cell clones isolated from rheumatoid arthritis patients: Possible involvement of TNF-α in reduction of osteoprotegerin in synovium

Cytokine

Volumn 41, Issue 1, 2008, Pages 61-70

  Zhao, Baohong ^a   Takami, Masamichi ^a   Miyamoto, Yoichi ^a   Suzawa, Tetsuo ^a   Yamada, Atsushi ^a   Mochizuki, Ayako ^a   Yasuhara, Rika ^a   Wang, Xiaogu ^a   Inoue, Tomio ^a   Namiki, Osamu ^a   Sakamoto, Keizo ^a   Kamijo, Ryutaro ^a  

^a SHOWA UNIVERSITY   (Japan)

Author keywords

Apoptosis; Infliximab; Osteoprotegerin; Rheumatoid arthritis; TNF

Indexed keywords

INFLIXIMAB; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTICLE; BONE DESTRUCTION; CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; FIBROBLAST; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; NICK END LABELING; OSTEOCLAST; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SYNOVIOCYTE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; APOPTOSIS; ARTHRITIS, RHEUMATOID; CELL DIFFERENTIATION; CELL SURVIVAL; CELLS, CULTURED; FEMALE; FIBROBLASTS; HUMANS; MALE; MIDDLE AGED; OSTEOCLASTS; OSTEOPROTEGERIN; RANK LIGAND; SYNOVIAL MEMBRANE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 37449001820     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2007.10.013     Document Type: Article

References (53)

1. Gravallese E.M., Manning C., Tsay A., Naito A., Pan C., Amento E., et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 43 (2000) 250-258
2. Takayanagi H., Iizuka H., Juji T., Nakagawa T., Yamamoto A., Miyazaki T., et al. Involvement of receptor activator of nuclear factor κB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 43 (2000) 259-269
3. Itonaga I., Fujikawa Y., Sabokbar A., Murray D.W., and Athanasou N.A. Rheumatoid arthritis synovial macrophage-osteoclast differentiation is osteoprotegerin ligand-dependent. J Pathol 192 (2000) 97-104
4. Goldring S.R. Pathogenesis of bone erosions in rheumatoid arthritis. Curr Opin Rheumatol 14 (2002) 406-410
5. Schett G., and Smolen J.S. New insights in the mechanism of bone loss in arthritis. Curr Pharm Des 11 (2005) 3039-3049
6. Wong B.R., Rho J., Arron J., Robinson E., Orlinick J., Chao M., et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem 272 (1997) 25190-25194
7. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95 (1998) 3597-3602
8. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93 (1998) 165-176
9. Anderson D.M., Maraskovsky E., Billingsley W.L., Dougall W.C., Tometsko M.E., Roux E.R., et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390 (1997) 175-179
10. Kong Y.Y., Feige U., Sarosi I., Bolon B., Tafuri A., Morony S., et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402 (1999) 304-309
11. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luthy R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89 (1997) 309-319
12. Sakata M., Shiba H., Komatsuzawa H., Fujita T., Ohta K., Sugai M., et al. Expression of osteoprotegerin (osteoclastogenesis inhibitory factor) in cultures of human dental mesenchymal cells and epithelial cells. J Bone Miner Res 14 (1999) 1486-1492
13. Vidal N.O., Brandstrom H., Jonsson K.B., and Ohlsson C. Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: down-regulation by glucocorticoids. J Endocrinol 159 (1998) 191-195
14. Collin-Osdoby P., Rothe L., Anderson F., Nelson M., Maloney W., and Osdoby P. Receptor activator of NF-κB and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem 276 (2001) 20659-20672
15. Mitani M., Miura Y., Saura R., Kitagawa A., Fukuyama T., Hashiramoto A., et al. Estrogen specifically stimulates expression and production of osteoprotegerin from rheumatoid synovial fibroblasts. Int J Mol Med 15 (2005) 827-832
16. Zannettino A.C., Holding C.A., Diamond P., Atkins G.J., Kostakis P., Farrugia A., et al. Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. J Cell Physiol 204 (2005) 714-723
17. Haynes D.R., Barg E., Crotti T.N., Holding C., Weedon H., Atkins G.J., et al. Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls. Rheumatology (Oxford) 42 (2003) 123-134
18. Kotake S., Udagawa N., Hakoda M., Mogi M., Yano K., Tsuda E., et al. Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum 44 (2001) 1003-1012
19. Redlich K., Hayer S., Maier A., Dunstan C.R., Tohidast-Akrad M., Lang S., et al. Tumor necrosis factor α-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum 46 (2002) 785-792
20. Criscione L.G., and St. Clair E.W. Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases. Curr Opin Rheumatol 14 (2002) 204-211
21. Goetz F.W., Planas J.V., and MacKenzie S. Tumor necrosis factors. Dev Comp Immunol 28 (2004) 487-497
22. Lipsky P.E., van der Heijde D.M., St. Clair E.W., Furst D.E., Breedveld F.C., Kalden J.R., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343 (2000) 1594-1602
23. Maini R.N., and Feldmann M. How does infliximab work in rheumatoid arthritis?. Arthritis Res 4 Suppl. 2 (2002) S22-S28
24. Maini R.N., Breedveld F.C., Kalden J.R., Smolen J.S., Furst D., Weisman M.H., et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 50 (2004) 1051-1065
25. Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., Cooper N.S., et al. The American Rheumatism Association 1987 Revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31 (1988) 315-324
26. Goto M., Sasano M., Yamanaka H., Miyasaka N., Kamatani N., Inoue K., et al. Spontaneous production of an interleukin 1-like factor by cloned rheumatoid synovial cells in long-term culture. J Clin Invest 80 (1987) 786-796
27. Takami M., Cho E.S., Lee S.Y., Kamijo R., and Yim M. Phosphodiesterase inhibitors stimulate osteoclast formation via TRANCE/RANKL expression in osteoblasts: possible involvement of ERK and p38 MAPK pathways. FEBS Lett 579 (2005) 832-838
28. Pap T., Muller-Ladner U., Gay R.E., and Gay S. Fibroblast biology. Role of synovial fibroblasts in the pathogenesis of rheumatoid arthritis. Arthritis Res 2 (2000) 361-367
29. Wu Y., Liu J., Feng X., Yang P., Xu X., Hsu H.C., et al. Synovial fibroblasts promote osteoclast formation by RANKL in a novel model of spontaneous erosive arthritis. Arthritis Rheum 52 (2005) 3257-3268
30. Lee H.Y., Jeon H.S., Song E.K., Han M.K., Park S.I., Lee S.I., et al. CD40 ligation of rheumatoid synovial fibroblasts regulates RANKL-mediated osteoclastogenesis: evidence of NF-κB-dependent, CD40-mediated bone destruction in rheumatoid arthritis. Arthritis Rheum 54 (2006) 1747-1758
31. De Bari C., Dell'Accio F., Tylzanowski P., and Luyten F.P. Multipotent mesenchymal stem cells from adult human synovial membrane. Arthritis Rheum 44 (2001) 1928-1942
32. Nishimura K., Solchaga L.A., Caplan A.I., Yoo J.U., Goldberg V.M., and Johnstone B. Chondroprogenitor cells of synovial tissue. Arthritis Rheum 42 (1999) 2631-2637
33. Seto H., Kamekura S., Miura T., Yamamoto A., Chikuda H., Ogata T., et al. Distinct roles of Smad pathways and p38 pathways in cartilage-specific gene expression in synovial fibroblasts. J Clin Invest 113 (2004) 718-726
34. Crotti T.N., Smith M.D., Weedon H., Ahern M.J., Findlay D.M., Kraan M., et al. Receptor activator NF-κB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis. Ann Rheum Dis 61 (2002) 1047-1054
35. Manabe N., Kawaguchi H., Chikuda H., Miyaura C., Inada M., Nagai R., et al. Connection between B lymphocyte and osteoclast differentiation pathways. J Immunol 167 (2001) 2625-2631
36. Wei S., Kitaura H., Zhou P., Ross F.P., and Teitelbaum S.L. IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest 115 (2005) 282-290
37. Emery J.G., McDonnell P., Burke M.B., Deen K.C., Lyn S., Silverman C., et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 273 (1998) 14363-14367
38. Miyashita T., Kawakami A., Nakashima T., Yamasaki S., Tamai M., Tanaka F., et al. Osteoprotegerin (OPG) acts as an endogenous decoy receptor in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis of fibroblast-like synovial cells. Clin Exp Immunol 137 (2004) 430-436
39. Ziolkowska M., Kurowska M., Radzikowska A., Luszczykiewicz G., Wiland P., Dziewczopolski W., et al. High levels of osteoprotegerin and soluble receptor activator of nuclear factor κB ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. Arthritis Rheum 46 (2002) 1744-1753
40. Firestein G.S., Yeo M., and Zvaifler N.J. Apoptosis in rheumatoid arthritis synovium. J Clin Invest 96 (1995) 1631-1638
41. Nakajima T., Aono H., Hasunuma T., Yamamoto K., Shirai T., Hirohata K., et al. Apoptosis and functional Fas antigen in rheumatoid arthritis synoviocytes. Arthritis Rheum 38 (1995) 485-491
42. Tsuboi M., Eguchi K., Kawakami A., Matsuoka N., Kawabe Y., Aoyagi T., et al. Fas antigen expression on synovial cells was down-regulated by interleukin 1 β. Biochem Biophys Res Commun 218 (1996) 280-285
43. Kawakami A., Eguchi K., Matsuoka N., Tsuboi M., Kawabe Y., Aoyagi T., et al. Inhibition of Fas antigen-mediated apoptosis of rheumatoid synovial cells in vitro by transforming growth factor β 1. Arthritis Rheum 39 (1996) 1267-1276
44. Smith C.A., Farrah T., and Goodwin R.G. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 76 (1994) 959-962
45. Vandenabeele P., Declercq W., Beyaert R., and Fiers W. Two tumour necrosis factor receptors: structure and function. Trends Cell Biol 5 (1995) 392-399
46. Wiegmann K., Schutze S., Kampen E., Himmler A., Machleidt T., and Kronke M. Human 55-kDa receptor for tumor necrosis factor coupled to signal transduction cascades. J Biol Chem 267 (1992) 17997-18001
47. Hsu H., Xiong J., and Goeddel D.V. The TNF receptor 1-associated protein TRADD signals cell death and NF-κB activation. Cell 81 (1995) 495-504
48. Liu Z.G., Hsu H., Goeddel D.V., and Karin M. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-κB activation prevents cell death. Cell 87 (1996) 565-576
49. Natoli G., Costanzo A., Ianni A., Templeton D.J., Woodgett J.R., Balsano C., et al. Activation of SAPK/JNK by TNF receptor 1 through a noncytotoxic TRAF2-dependent pathway. Science 275 (1997) 200-203
50. Beg A.A., and Baltimore D. An essential role for NF-κB in preventing TNF-alpha-induced cell death. Science 274 (1996) 782-784
51. Van Antwerp D.J., Martin S.J., Kafri T., Green D.R., and Verma I.M. Suppression of TNF-α-induced apoptosis by NF-κB. Science 274 (1996) 787-789
52. Catrina A.I., af Klint E., Ernestam S., Catrina S.B., Makrygiannakis D., Botusan I.R., et al. Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis. Arthritis Rheum 54 (2006) 76-81
53. Lee C.K., Lee E.Y., Chung S.M., Mun S.H., Yoo B., and Moon H.B. Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor κB, osteoprotegerin, and receptor activator of nuclear factor κB ligand. Arthritis Rheum 50 (2004) 3831-3843